Table 1 Overview of investigational non-PARP inhibitors in EOC maintenance
Trial name [ClinicalTrials. gov identifier] | Drug | Mono/Combo; Phase | Patient population and key eligibility | N | Treatment arms | Primary endpoint | Results |
|---|---|---|---|---|---|---|---|
GOG 212 [42] | Paclitaxel | Mono; Phase III | Advanced EOC in complete response | 1157 | Pac IV or CT-2103 (PP) | OS | No improvement in OS; increased toxicities |
ICON 7 [44] | Bevacizumab | Combo; Phase III | Newly diagnosed early or advance EOC, first line | 1528 | C + Pac vs C + Pac + bev | PFS and OS | No improvement in PFS. No improvement in OS: restricted mean survival time chemo vs bev group 44.6 months (95% CI 43.2–45.9) vs 45.5 months (CI 44.2–46.7); log-rank (p = 0.85) Benefit only in high-risk subset: mean OS 34.5 months (95% CI 32.0–37.0) vs 39.3 months (37.0–41.7) (log-rank p = 0.03). |
GOG 218 [43] | Bevacizumab | Combo; Phase III | Newly diagnosed advance EOC | 1873 | C + Pac (TC group) vs C + Pac + bev (TCP group) vs C + Pac + bev followed by bev maintenance | PFS and OS | PFS improvement of 3.8 months (10.3 for standard chemotherapy, 14.1 months for the maintenance regimen), Median OS was not significantly different between arms |
NCT02022917 [43] | Bevacizumab | Combo; Phase II | Extensive stage IIIC or IV EOC | 27 | Postoperative PBC + adjuvant and maintenance bev | AEs | Ongoing; study completion Dec 2018 |
ATALANTE (NCT02891824) | Atezolizumab | Combo; Phase III | Late relapse EOC | 405 | Atezolizumab in combination with PBC + bev administered concurrent to chemotherapy and in maintenance | PFS | Ongoing; study completion 2023 |
Pazopanib | Mono; Phase III | Platinum-sensitive maintenance in EOC | 940 | Pazopanib 800 mg OD maintenance in EOC patients who did not progress after one line of chemotherapy | PFS | Improved median PFS vs placebo 17.9 vs 12.3 months, respectively (HR: 0.77; 95% CI, 0.64–0.91; p = 0.0021) |